FGF basic

FGF basic Informations sur la molécule

Nom anglais	Fibroblast growth factor 2	Nombre de médicaments commercialisés	1
Nombre de médicaments cliniques	4	Alias de la cible	FGF-2，Heparin-binding growth factor 2，Basic fibroblast growth factor，FGFB，bFGF，HBGF-2，FGF2，Fibroblast Growth Factor 2 (Basic)，Basic Fibroblast Growth Factor BFGF，Prostatropin，Fibroblast Growth Factor 2
Phase de R&D la plus avancée	Approved

Nom anglais	Fibroblast growth factor 2
Alias de la cible	FGF-2，Heparin-binding growth factor 2，Basic fibroblast growth factor，FGFB，bFGF，HBGF-2，FGF2，Fibroblast Growth Factor 2 (Basic)，Basic Fibroblast Growth Factor BFGF，Prostatropin，Fibroblast Growth Factor 2
Nombre de médicaments commercialisés	1
Nombre de médicaments cliniques	4
Phase de R&D la plus avancée	Approved

FGF basic Liste de produits

Attribut
Protein (7)Kits (1)
Bibliothèque de produits
En ligne (8)
Espèces
Human (8)
Étiquette
Tag Free (6)His Tag & Avi Tag (1)- (1)
Marqueur
Unconjugated (6)Biotin-labeled (1)- (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
HOT BFF-H4117	Human	E. coli	Human FGF basic Protein, premium grade	Ajouter au panier
HOT BFF-H5115	Human	E. coli	Human FGF basic (154aa) Protein, premium grade	Ajouter au panier
HOT GMP-FGCH17	Human	E. coli	GMP Human FGF basic Protein	Ajouter au panier
BFF-H4118	Human	E. coli	Human FGF basic Protein, Research Grade	Ajouter au panier
BFF-H5113	Human	E. coli	Human FGF basic Superior Stable Mutant Protein, premium grade	Ajouter au panier
BFF-H5114	Human	E. coli	Human FGF basic Superior Stable Mutant Protein, Research Grade	Ajouter au panier
CEA-C082	Human	-	Human bFGF/FGF2 ELISA Kit	Ajouter au panier
FGC-H81E3	Human	E. coli	Biotinylated Human FGF basic Protein, Avitag™,His Tag (HPLC verified)	Ajouter au panier

Quantité totale8

FGF basicContexte de la molécule

FGF basic is a member of the FGF family of at least 23 related mitogenic proteins which show 35-60% amino acid conservation. FGF acidic and basic, unlike the other members of the family, lack signal peptides and are apparently secreted by mechanisms other than the classical protein secretion pathway. FGF basic has been isolated from a number of sources, including neural tissue, pituitary, adrenal cortex, corpus luteum, and placenta. This factor contains four cysteine residues, but reduced FGF basic retains full biological activity, indicating that disulfide bonds are not required for this activity. bFGF is a critical component of human embryonic stem cell culture medium; the growth factor is necessary for the cells to remain in an undifferentiated state, although the mechanisms by which it does this are poorly defined. It has been demonstrated to induce gremlin expression which in turn is known to inhibit the induction of differentiation by bone morphogenetic proteins. It is necessary in mouse-feeder cell dependent culture systems, as well as in feeder and serum-free culture systems.

FGF basicAlias de la molécule

FGF2,BFGF,FGFB,FGF basic,HBGF-2

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Muparfostat sodium	PI-88	Phase 3 Clinical	Australian National University	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Prostatic Neoplasms; Skin Melanoma; Solid tumours	Details
RBM-007	ID3 (21); APT-F2; RBM-007	Phase 2 Clinical	Ribomic	Achondroplasia; Macular Degeneration	Details
Fibroblast growth factor 2 gene therapy (ID Pharma)	SeV-10101; SEV-10101; DVC-10101; BF-30	Phase 2 Clinical	Dnavec	Arterial Occlusive Diseases; Intermittent Claudication; Ischemia; Peripheral Arterial Disease; Peripheral arterial occlusive disorders	Details
Recombinant Human Epidermal Growth Factor Derivative Gel (Uni-Bio Science)		Phase 1 Clinical	Uni-Bio Science Group	Wounds and Injuries	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Thalidomide	NSC-66847; NSC-527179; K-17; FPF-300; FPF300	Approved	Celgene Corp	Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled	Mainland China	Leprosy, Lepromatous; Multiple Myeloma	Changzhou Pharmaceutical Factory	1982-01-01	Acquired Immunodeficiency Syndrome; Adenocarcinoma, Clear Cell; Adenoma, Islet Cell; Amyotrophic Lateral Sclerosis; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Angiodysplasia; Appendiceal Neoplasms; Arachnoiditis; Arteriovenous Malformations; Axial Spondyloarthritis; beta-Thalassemia; Burning Mouth Syndrome; Carcinoid Tumor; Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Cholangitis, Sclerosing; Colorectal Neoplasms; Cough; Endometrial Neoplasms; Endometriosis; Epilepsy; Erythema Nodosum; Gastric Antral Vascular Ectasia; Gastrointestinal Hemorrhage; Genetic Diseases, Inborn; Glioma; Graft vs Host Disease; Head and Neck Neoplasms; Hemoglobinopathies; HIV Infections; HIV Wasting Syndrome; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypertension, Portal; Idiopathic Pulmonary Fibrosis; Kidney Neoplasms; Leiomyosarcoma; Leprosy, Lepromatous; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Liver Neoplasms; Lung Neoplasms	Details